Articles for the ‘’ Category

Over the Christmas break, the Belgian Parliament adopted an urgent law with several measures linked to the approved 2026 healthcare budget, with effect from 1 January 2026. The law is intentionally limited to provisions that must enter into force immediately to ensure that the required savings and revenues are available from the start of the budget year. Several measures are directly relevant for pharma companies. This blog post highlights the key takeaways and briefly examines the central budgetary provisions affecting the sector.